Cargando…

Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3

The role of phosphodiesterase 3 (PDE3), a cyclic AMP (cAMP)-degrading enzyme, in modulating gluconeogenesis remains unknown. Here, linderane, a natural compound, was found to inhibit gluconeogenesis by activating hepatic PDE3 in rat primary hepatocytes. The underlying molecular mechanism and its eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Wei, Ye, Yangliang, Feng, Ying, Xu, Tifei, Huang, Suling, Shen, Jianhua, Leng, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962748/
https://www.ncbi.nlm.nih.gov/pubmed/29867482
http://dx.doi.org/10.3389/fphar.2018.00476
_version_ 1783324932862640128
author Xie, Wei
Ye, Yangliang
Feng, Ying
Xu, Tifei
Huang, Suling
Shen, Jianhua
Leng, Ying
author_facet Xie, Wei
Ye, Yangliang
Feng, Ying
Xu, Tifei
Huang, Suling
Shen, Jianhua
Leng, Ying
author_sort Xie, Wei
collection PubMed
description The role of phosphodiesterase 3 (PDE3), a cyclic AMP (cAMP)-degrading enzyme, in modulating gluconeogenesis remains unknown. Here, linderane, a natural compound, was found to inhibit gluconeogenesis by activating hepatic PDE3 in rat primary hepatocytes. The underlying molecular mechanism and its effects on whole-body glucose and lipid metabolism were investigated. The effect of linderane on gluconeogenesis, cAMP content, phosphorylation of cAMP-response element-binding protein (CREB) and PDE activity were examined in cultured primary hepatocytes and C57BL/6J mice. The precise mechanism by which linderane activates PDE3 and inhibits the cAMP pathway was explored using pharmacological inhibitors. The amelioration of metabolic disorders was observed in ob/ob mice. Linderane inhibited gluconeogenesis, reduced phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) gene expression, and decreased intracellular cAMP concentration and CREB phosphorylation in rat primary hepatocytes under both basal and forskolin-stimulated conditions. In rat primary hepatocytes, it also increased total PDE and PDE3 activity but not PDE4 activity. The suppressive effect of linderane on the cAMP pathway and gluconeogenesis was abolished by the non-specific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the specific PDE3 inhibitor cilostazol. Linderane indirectly activated PDE3 through extracellular regulated protein kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) activation. Linderane improved glucose and lipid metabolism after chronic oral administration in ob/ob mice. Our findings revealed linderane as an indirect PDE3 activator that suppresses gluconeogenesis through cAMP pathway inhibition and has beneficial effects on metabolic syndromes in ob/ob mice. This investigation highlighted the potential for PDE3 activation in the treatment of type 2 diabetes.
format Online
Article
Text
id pubmed-5962748
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59627482018-06-04 Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3 Xie, Wei Ye, Yangliang Feng, Ying Xu, Tifei Huang, Suling Shen, Jianhua Leng, Ying Front Pharmacol Pharmacology The role of phosphodiesterase 3 (PDE3), a cyclic AMP (cAMP)-degrading enzyme, in modulating gluconeogenesis remains unknown. Here, linderane, a natural compound, was found to inhibit gluconeogenesis by activating hepatic PDE3 in rat primary hepatocytes. The underlying molecular mechanism and its effects on whole-body glucose and lipid metabolism were investigated. The effect of linderane on gluconeogenesis, cAMP content, phosphorylation of cAMP-response element-binding protein (CREB) and PDE activity were examined in cultured primary hepatocytes and C57BL/6J mice. The precise mechanism by which linderane activates PDE3 and inhibits the cAMP pathway was explored using pharmacological inhibitors. The amelioration of metabolic disorders was observed in ob/ob mice. Linderane inhibited gluconeogenesis, reduced phosphoenolpyruvate carboxykinase (Pck1) and glucose-6-phosphatase (G6pc) gene expression, and decreased intracellular cAMP concentration and CREB phosphorylation in rat primary hepatocytes under both basal and forskolin-stimulated conditions. In rat primary hepatocytes, it also increased total PDE and PDE3 activity but not PDE4 activity. The suppressive effect of linderane on the cAMP pathway and gluconeogenesis was abolished by the non-specific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) and the specific PDE3 inhibitor cilostazol. Linderane indirectly activated PDE3 through extracellular regulated protein kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) activation. Linderane improved glucose and lipid metabolism after chronic oral administration in ob/ob mice. Our findings revealed linderane as an indirect PDE3 activator that suppresses gluconeogenesis through cAMP pathway inhibition and has beneficial effects on metabolic syndromes in ob/ob mice. This investigation highlighted the potential for PDE3 activation in the treatment of type 2 diabetes. Frontiers Media S.A. 2018-05-15 /pmc/articles/PMC5962748/ /pubmed/29867482 http://dx.doi.org/10.3389/fphar.2018.00476 Text en Copyright © 2018 Xie, Ye, Feng, Xu, Huang, Shen and Leng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xie, Wei
Ye, Yangliang
Feng, Ying
Xu, Tifei
Huang, Suling
Shen, Jianhua
Leng, Ying
Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title_full Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title_fullStr Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title_full_unstemmed Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title_short Linderane Suppresses Hepatic Gluconeogenesis by Inhibiting the cAMP/PKA/CREB Pathway Through Indirect Activation of PDE 3 via ERK/STAT3
title_sort linderane suppresses hepatic gluconeogenesis by inhibiting the camp/pka/creb pathway through indirect activation of pde 3 via erk/stat3
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962748/
https://www.ncbi.nlm.nih.gov/pubmed/29867482
http://dx.doi.org/10.3389/fphar.2018.00476
work_keys_str_mv AT xiewei linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT yeyangliang linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT fengying linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT xutifei linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT huangsuling linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT shenjianhua linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3
AT lengying linderanesuppresseshepaticgluconeogenesisbyinhibitingthecamppkacrebpathwaythroughindirectactivationofpde3viaerkstat3